Copyright
©The Author(s) 2017.
World J Gastroenterol. Jun 21, 2017; 23(23): 4181-4190
Published online Jun 21, 2017. doi: 10.3748/wjg.v23.i23.4181
Published online Jun 21, 2017. doi: 10.3748/wjg.v23.i23.4181
Figure 7 Senicapoc prevents lipid-induced apoptosis.
HepG2 cells were treated with Senicapoc (0-10 μmol/L) and then loaded with palimitic acid (75-150 μmol/L). Following overnight incubation, apoptosis was measured using the Caspase Glo assay. Treatment with Senicapoc decreased palmitic acid-driven HepG2 cell death [aP < 0.05 vs corresponding control (0 μmol/L Senicapoc) at each concentration of palmitic acid].
- Citation: Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Yamin M, Goldberg ID, Narayan P. Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease. World J Gastroenterol 2017; 23(23): 4181-4190
- URL: https://www.wjgnet.com/1007-9327/full/v23/i23/4181.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i23.4181